APA (7th ed.) Citation

Khabirov, F. A., Khaibullin, T. I., Granatov, E. V., Babicheva, N. N., Aver’yanova, L. A., & Shakirzyanova, S. R. (2017). RESULTS OF AN OPEN-LABEL COMPARATIVE RANDOMIZED CLINICAL TRIAL OF AXOGLATIRAN® FS (F-SINTEZ, RUSSIA) EFFICIENCY AND SAFETY IN COMPARISON WITH COPAXONE®-TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS. ABV-press.

Chicago Style (17th ed.) Citation

Khabirov, F. A., T. I. Khaibullin, E. V. Granatov, N. N. Babicheva, L. A. Aver’yanova, and S. R. Shakirzyanova. RESULTS OF AN OPEN-LABEL COMPARATIVE RANDOMIZED CLINICAL TRIAL OF AXOGLATIRAN® FS (F-SINTEZ, RUSSIA) EFFICIENCY AND SAFETY IN COMPARISON WITH COPAXONE®-TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS. ABV-press, 2017.

MLA (9th ed.) Citation

Khabirov, F. A., et al. RESULTS OF AN OPEN-LABEL COMPARATIVE RANDOMIZED CLINICAL TRIAL OF AXOGLATIRAN® FS (F-SINTEZ, RUSSIA) EFFICIENCY AND SAFETY IN COMPARISON WITH COPAXONE®-TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS. ABV-press, 2017.